EnVivo Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial Program of EVP-0962 in Alzheimer’s Disease
Published: Jan 03, 2013
WATERTOWN, Mass.--(BUSINESS WIRE)--EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today announced the initiation of a Phase 2 clinical trial of EVP-0962, its potent and selective gamma secretase modulator (GSM), in healthy volunteers and in volunteers with mild cognitive impairment or early Alzheimer’s disease. The Phase 2 trial is a randomized, double-blind, dose escalating study to assess the safety, tolerability, pharmacokinetics and effects of EVP-0962 on cerebral spinal fluid amyloid concentrations.